Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01593020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT01585870
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
- Conditions
- Breast Cancer Nos Metastatic RecurrentMalignant Solid TumourNeuropathy
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 44
- Registration Number
- NCT01554371
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
- Conditions
- HER2 Negative Breast Cancer
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01527487
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
- Conditions
- Breast NeoplasmsBreast TumorsBreast CancerTumors, BreastCancer of the BreastNeoplasms, Breast
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 7
- Registration Number
- NCT01498588
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
- First Posted Date
- 2011-11-02
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 963
- Registration Number
- NCT01463891
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT01458249
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT01454934
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
- Conditions
- Estrogen Receptor Positive TumorBreast Cancer
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01439282
- Locations
- 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Arizona Oncology Associates, PC - CASA, Tucson, Arizona, United States
🇺🇸Sciode Medical Associates, PLLC, d.b.a. Eastchester Center, Bronx, New York, United States
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01432886
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.